Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5, 11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors

Article abstract of DOI:10.3390/molecules22111739

Under the guidance of combination of traditional Chinese medicine chemistry (CTCMC), this study describes the preparation of a phenolic acid/dipeptide/borneol hybrid consisting of phenolic acid and a bornyl moiety connected to the dipeptide N-terminal and C-terminal respectively. It also evaluates their angiotensin converting enzyme (ACE) inhibitory and synergistic antihypertensive activities. Briefly, a series of novel 2-hydroxypyrrolobenzodiazepine-5, 11-dione analogues were prepared and investigated for their ability to inhibit ACE. The influence of the phenolic acid and bornyl moiety on subsite selectivity is also demonstrated. Among all the new compounds, two compounds-7a and 7g-reveal good inhibition potency in in vitro ACE-inhibitory tests. Interestingly, favorable binding results in molecular docking studies also supported the in vitro results. Additionally, the bioassay showed that oral administration of the two compounds displayed high and long-lasting antihypertensive activity both in acute antihypertensive tests and in therapeutic antihypertensive tests by non-invasive blood pressure measurements in spontaneously hypertensive rats.

Full text of DOI:10.3390/molecules22111739

molecules
Article
Design, Synthesis, and Evaluation of Novel Phenolic
Acid/Dipeptide/Borneol Hybrids as Potent
Angiotensin Converting Enzyme (ACE) Inhibitors
with Anti-hypertension Activity
Ying Sun 1,†, Yujun Bai 1,†, Xirui He 1, Yajun Bai 1,2, Pei Liu 1, Zefeng Zhao 1, Xufei Chen 1 and
Xiaohui Zheng 1,
*
1
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education,
Northwest University, Xi’an 710069, China; syqsn1108@163.com (Y.S.); tianleyu@163.com (Y.B.);
6105194@163.com (X.H.); baiyj@nwu.edu.cn (Y.B.); lp183929@163.com (P.L.); zzf598155752@sina.com (Z.Z.);
m13085333798@163.com (X.C.)
Key Laboratory of Synthetic and Natural Functional Molecule Chemistry of the Ministry of Education,
College of Chemistry 0026 Materials Science, Northwest University, Xi’an 710127, China
Correspondence: zhengxh@nwu.edu.cn
2
*
†
These authors contributed equally to this paper and share co-first authorship.
Received: 27 September 2017; Accepted: 9 October 2017; Published: 3 November 2017
Abstract: Under the guidance of combination of traditional Chinese medicine chemistry (CTCMC),
this study describes the preparation of a phenolic acid/dipeptide/borneol hybrid consisting
of phenolic acid and a bornyl moiety connected to the dipeptide N-terminal and C-terminal
respectively. It also evaluates their angiotensin converting enzyme (ACE) inhibitory and synergistic
antihypertensive activities. Briefly, a series of novel phenolic acid/dipeptide/borneol hybrids
were prepared and investigated for their ability to inhibit ACE. The influence of the phenolic acid
and bornyl moiety on subsite selectivity is also demonstrated. Among all the new compounds,
two compounds—7a and 7g—reveal good inhibition potency in in vitro ACE-inhibitory tests.
Interestingly, favorable binding results in molecular docking studies also supported the in vitro
results. Additionally, the bioassay showed that oral administration of the two compounds
displayed high and long-lasting antihypertensive activity both in acute antihypertensive tests and in
therapeutic antihypertensive tests by non-invasive blood pressure measurements in spontaneously
hypertensive rats.
Keywords: phenolic acid/dipeptide/borneol hybrid; ACE inhibitor; hypertension; combination of
traditional Chinese medicine chemistry
1. Introduction
Hypertension is a metabolic cardiovascular syndrome that affects nearly one billion people around
the world [
1,2]. Clinically, it is the major risk factor for various heart diseases, such as arteriosclerosis,
coronary heart disease, stroke, peripheral arterial disease, and heart failure [3,4
]. Nowadays, the
angiotensin converting enzyme (ACE) inhibitors (e.g., Capoten (captopril), Vasotec (enalapril), Prinivil,
or Zestril (lisinopril), etc.) have been considered as first-line drugs for the treatment of hypertension
and myocardial infarction [5,6]. However, it was found that any single currently used ACE inhibitor
cannot completely prevent and cure hypertension. Clinically, they are usually used in conjunction with
one or two other therapeutic agents including beta blockers, long-acting nitrate, and calcium channel
blockers for a better therapeutic effect (e.g., Enalapril/hydrochlorothiazide, Enalapril/Valsartan, and
Enalapril/nifedipine, etc.). Moreover, ACE inhibitors are also found to have some side effects, such as
Molecules 2017, 22, 1739; doi:10.3390/molecules22111739
www.mdpi.com/journal/molecules

Molecules 2017, 22, 1739
2 of 11
cough, elevated blood potassium levels, low blood pressure, and kidney failure [
trend has been toward developing safer and multi-functional ACE inhibitors.
7,8]. Therefore, the
Many pioneering work in the mid-1970s to mid-1990s revealed that the N-substituted derivative
of proline is an extremely potent ACE inhibitor [ 12]. Recently, during our study on compound
9–
Salvia recipe (including three Chinese herbal medicines: Salvia miltiorrhiza Bge. (Danshen),
Panax pseudoginseng Wall. (Sanqi), and Borneol (Bingpian, from Cinnamomum camphora (L.) Presl))
for searching new antihypertensive drugs, we noticed that the phenolic acids extract from Danshen
plays a pivotal role in regulating blood pressure, protecting against oxidative damage diseases, slightly
slowing the heart rate, and relaxing and widening blood vessels [13], while borneol may help other
medicinal molecules to penetrate cell membrane easily [14,15]. In fact, the molecular dimension of
some phenolic acids, especial those structures varying from C6–C1 to C6–C3, are more suitable for
ACE S1 subsite [16] and the hydroxyls on these phenolic acids may serve as good hydrogen donors to
chelate with Zn2+ in the active site of ACE [17]. More recently, some phenolic acids, such as ferulic acid,
gallic acid, chlorogenic acid, and caffeic acid, have been demonstrated to be a new class of selective
inhibitors of ACE [18,19]. So, in this study, based on the effectiveness of compound Salvia recipe in the
prevention and treatment of angiocardiopathy and the ideas of CTCMC, we tried to add these effective
phenolic acid and bornyl moieties simultaneously to the N-terminal and C-terminal of dipeptides
(Val or Leu-Pro, the core structure of some lead ACE inhibitors [20–22]) (see Figure 1) by simply using
amide and ester bonds, respectively. We envision that this molecular construction strategy may result
in producing more novel lead compounds with multi-functions, not only targeting ACE, but also other
targets relating to synergistic hypotensive effects, which can overcome some side effects of current
ACE inhibitors.
Figure 1. Structure design inspired by the formula of compound Salvia recipe and classical angiotensin
converting enzyme (ACE) inhibitors. VPP: valine-proline-proline; IPP: isoleucine-proline-proline.
2. Materials and Methods
2.1. Synthesis and Preparation of 7a–7h
Commercially available L-proline
di-tert-butyl dicarbonate in good yield and then followed by bornyl ester formation under Steglich
esterification conditions to afford N-Boc-Pro-bornyl ester . This was subjected to trifluoracetic
acid(TFA)/dichloromethane(DCM) conditions to afford compound , which was coupled with
1 was initially converted to N-Boc-Proline 2 in the presence of
3
4
N-Boc-Val and N-Boc-Leu respectively under the 1-ethyl-3-(3-dimethyllaminopropyl) carbodiimide
hydrochloride(EDCI)/1-hydroxybenzotriazole (HOBT) system to furnish the corresponding
N-Boc-dipeptide ester 5a and 5b
with the above mentioned TFA/DCM conditions to give 6a and 6b in near-quantitative yields.
Finally, the target compounds 7a 7h were achieved by general coupling reaction of 5a and 5b
with corresponding phenolic acids under the benzotriazole-1-yl-oxytripyrrolidinophosphonium
. Removal of the Boc group of 5a and 5b was accomplished
–

Molecules 2017, 22, 1739
3 of 11
hexafluorophosphate(Pybop)/N,N-diisopropyl-ethylamine (DIPEA) system. The synthesis of the
new ACE inhibitors 7a–7h is shown in Scheme 1.
Scheme 1. Synthesis of ◦new ACE Inhibitors 7a
–7h. Reagents, conditions, and yields: (a) (Boc)O2,
dioxane/H2O, NaOH, 0 C–25 C, 12 h, 86% isolated yield; (b) EDCI, DMAP, (+)-borneol, THF, room
◦
temperature, 18 h, 75% isolated yield; (
) EDCI, HOBT, corresponding Boc-protective amino acid, DMF, room temperature, 10–20 h; (
TFA:DCM = 1:4, room temperature, 4–8 h; ( ) corresponding phenolic acids, Pybop, DIPEA, THF, DMF
c) TFA:DCM = 1:5, room temperature, 6 h, 91% isolated yield;
(
d
e)
f
or DMSO, room temperature, under nitrogen atmosphere, 12–30 h.
2.2. Biological Investigations
2.2.1. In Vitro ACE-Inhibitory Activity
The in vitro ACE-inhibitory activity of the newly synthesized compounds was evaluated using
ACE inhibition assay (Sigma-aldrich, St. Louis, MO, USA, No. A-6778). The experiments were carried
out for all the designed compounds (7a
(0.01–10 M). Lisinopril, a well-known ACE inhibitor drug, was used as standard for comparison with
the inhibitory activity of synthesized compounds. The ACE-inhibitory activity can be calculated by
the following equation: ACE-inhibitory activity (inhibition rate %) = [(Ablank1 Asample)/(Ablank1
Ablank2)] 100, where blank 1: Positive control (without ACE inhibition) and blank 2: Reagent blank.
–7h), for ACE-inhibitory activity at five different concentrations
µ
−
−
×
Then we measured and calculated the IC50 values of the designed compounds (7a–7h).
2.2.2. Molecular Docking Study
To gain insight into the interaction of ACE with the most potent compound, it was docked on
to tACE (PDB code: 1O86) using AutoDock Vina software (v4.2) (The Scripps Research Institute,
San Diego, CA, USA). Structures of the ligand were generated using ChemBioDraw Ultra (v13.0)
(Cambridgesoft, Billerica, MA, USA).
2.2.3. Antihypertensive Tests In Vivo
All the experiments were approved by the Institutional Animal Ethics Committee of Northwest
University. Experiments were carried out on spontaneously hypertension rats (SHRs) that were
9–10 weeks old and weighed 200–220 g. SHRs treated with normal saline were used as controls.
Lisinopril was used as a standard drug. Blood pressure (BP) was recorded automatically every day by
the indirect tail-cuff method using an electrosphygmomanometer (BP-2010A Storage Pressure Meter).
In acute antihypertensive tests in vivo, the most potent and active compounds obtained in in vitro
tests were measured using spontaneously hypertensive rats. The BP were measured before and 0.5, 1,
2, 3, 4, 5 and 6 h after a single dose of intragastrical administration of active compounds. In therapeutic

Molecules 2017, 22, 1739
4 of 11
antihypertensive tests, the more potent and active compound and lisinopril were treated orally for 7
consecutive days, and the BP was measured every day between drug delivery day and 14 days after
the drug treatment using an intelligent non-invasive blood pressure remote monitoring instrument.
3. Results and Discussion
3.1. Chemistry
The synthesis of target compounds 7a–7h was achieved following the procedures outlined in
Scheme 1. The chemical structure, synthetic conditions and yield of 7a–7h are shown in Scheme 2.
a
Scheme 2. Chemical structure, synthetic conditions and yield of 7a–7h. For the last step.

Molecules 2017, 22, 1739
5 of 11
Compound Identification (7a–7h)
1
(
7a). White powder. m/z = [M + 1] 487.2804, calculated value: 486.2729. H-NMR (600 MHz, CDCl3) δ
8.34 (s, 1H), 7.40 (dd, J = 30.8, 9.5 Hz, 1H), 7.31 (s, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.80 (d, J = 8.3 Hz, 1H),
4.98 (d, J = 9.9 Hz, 1H), 4.72 (t, J = 8.1 Hz, 1H), 4.46 (dd, J = 8.4, 4.6 Hz, 1H), 4.02–3.94 (m, 1H), 3.78–3.70
(m, 1H), 2.34–2.30 (m, 1H), 2.25–2.17 (m, 3H), 2.08–2.01 (m, 2H), 2.00–1.93 (m, 2H), 1.92–1.85 (m, 1H),
1.77–1.70 (m, 1H), 1.31–1.22 (m, 3H), 1.12 (d, J = 6.7 Hz, 3H), 1.04 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz,
1H), 0.97–0.95 (m, 1H), 0.89 (s, 3H), 0.86 (s, 3H), 0.81 (s, 3H). 13C NMR (151 MHz, CDCl3)
δ 172.22 (s),
171.83 (s), 168.25 (s), 148.42 (s), 144.02 (s), 125.46 (s), 120.53 (s), 115.10 (s), 114.29 (s), 81.03 (s), 59.57 (s),
56.76 (s), 49.09 (s), 48.13 (s), 44.91 (s), 36.46 (s), 31.47 (s), 29.83 (s), 29.48 (s), 28.04 (s), 27.21 (s), 24.94 (s),
19.81 (s), 19.51 (s), 18.93 (s), 18.63 (s), 13.74 (s).
1
(
7b). White powder. m/z = [M + 1] 501.2970, calculated value: 500.2886. H-NMR (600 MHz, CDCl3)
δ
7.41 (s, 1H), 6.99 (s, 1H), 6.68 (d, J = 12.4 Hz, 1H), 6.62–6.51 (m, 2H), 4.94 (d, J = 9.8 Hz, 1H), 4.55 (t, J =
8.1 Hz, 1H), 4.52–4.43 (m, 1H), 3.99–3.93 (m, 1H), 3.70–3.57 (m, 1H), 3.49–3.44 (m, 1H), 3.37 (d, J = 15.5
Hz, 1H), 2.33–2.26 (m, 1H), 2.24–2.19 (m, 1H), 2.09–1.94 (m, 5H), 1.89–1.84 (m, 1H), 1.79–1.67 (m, 2H),
1.35–1.15 (m, 3H), 1.03 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 7.3 Hz, 3H), 0.87 (s, 3H), 0.85 (s, 3H), 0.79 (s, 3H).
13C-NMR (151 MHz, CDCl3)
δ 173.05 (s), 172.12 (s), 171.41 (s), 125.94 (s), 121.52 (s), 116.33 (s), 115.93
(s), 115.49 (s), 81.01 (s), 59.58 (s), 56.40 (s), 49.03 (s), 48.09 (s), 47.75 (s), 44.87 (s), 42.75 (s), 36.46 (s), 31.29
(s), 29.50 (s), 28.04 (s), 27.20 (s), 24.99 (s), 19.80 (s), 19.41 (s), 18.91 (s), 18.37 (s), 18.02 (s), 13.71 (s).
1
(
7c). White powder. m/z = [M + 1] 527.3128, calculated value: 526.3042. H-NMR (600 MHz, CDCl3)
δ
8.22 (s, 1H), 7.51 (d, J = 15.5 Hz, 1H), 7.01 (d, J = 8.2 Hz, 1H), 6.98 (s, 1H), 6.89 (d, J = 8.1 Hz, 1H),
6.53 (d, J = 8.4 Hz, 1H), 6.29 (d, J = 15.5 Hz, 1H), 5.03–4.94 (m, 1H), 4.89–4.80 (m, 1H), 4.80–4.70 (m,
1H), 4.59–4.51 (m, 1H), 3.90 (dd, J = 16.2, 3.9 Hz, 3H), 3.77–3.69 (m, 1H), 3.67–3.55 (m, 1H), 2.36–2.30
(m, 1H), 2.26–2.21 (m, 1H), 2.18–2.11 (m, 1H), 2.10–2.01 (m, 3H), 1.94–1.88 (m, 1H), 1.78–1.72 (m, 1H),
1.71–1.66 (m, 1H), 1.29–1.24 (m, 2H), 1.10 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.89 (s, 3H), 0.87 (s,
3H), 0.81 (s, 3H). 13C-NMR (151 MHz, CDCl3)
δ 172.31 (s), 171.14 (s), 166.24 (s), 147.61 (s), 146.91 (s),
141.44 (s), 127.39 (s), 122.63 (s), 118.13 (s), 114.85 (s), 109.48 (s), 80.73 (s), 59.29 (s), 56.02 (s), 49.08 (s),
48.10 (s), 47.49 (s), 44.92 (s), 36.49 (s), 31.73 (s), 29.50 (s), 28.07 (s), 27.22 (s), 25.03 (s), 19.82 (s), 18.93 (s),
18.10 (s), 13.74 (s).
(
δ
7d). White powder. m/z = [M + 1] 503.2755, calculated value: 502.2679.1H-NMR (600 MHz, CDCl3)
8.34 (s, 1H), 7.46 (s, 1H), 7.48 (s, 1H), 7.33 (s, 2H), 5.00 (d, J = 9.8 Hz, 1H), 4.73 (t, J = 8.1 Hz, 1H),
4.48 (dd, J = 8.4, 4.6 Hz, 1H), 4.00–3.93 (m, 1H), 3.76–3.69 (m, 1H), 2.36–2.31 (m, 1H), 2.25–2.19 (m,
3H), 2.08–2.00 (m, 2H), 1.95–1.90 (m, 2H), 1.90–1.83 (m, 1H), 1.79–1.73 (m, 1H), 1.29–1.21 (m, 3H), 1.16
(d, J = 6.8 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.8 Hz, 1H), 0.98–0.95 (m, 1H), 0.91 (s, 3H), 0.87
(s, 3H), 0.80 (s, 3H). 13C-NMR (151 MHz, CDCl3)
δ 172.21 (s), 171.84 (s), 168.27 (s), 148.45 (s), 148.47 (s),
144.00 (s),120.58 (s), 114.31 (s), 81.02 (s), 59.55 (s), 56.78 (s), 49.06 (s), 48.17 (s), 44.90 (s), 36.44 (s), 31.43
(s), 29.85 (s), 29.44 (s), 28.02 (s), 27.25 (s), 24.97 (s), 19.85 (s), 19.52 (s), 18.94 (s), 18.65 (s), 13.75 (s).
1
(
7e). White solid. m/z = [M + 1] 501.2970, calculated value: 500.2886. H-NMR (600 MHz, CDCl3)
δ
8.41 (s, 1H), 7.45 (s, 1H), 7.31 (s, 1H), 7.18 (d, J = 8.3 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 5.03–4.98 (m, 1H),
4.55 (dd, J = 8.6, 4.3 Hz, 1H), 3.72–3.62 (m, 1H), 3.53–3.38 (m, 1H), 3.33–3.21 (m, 1H), 2.41–2.34 (m, 1H),
2.24–2.19 (m, 1H), 2.00–1.92 (m, 2H), 1.91–1.84 (m, 1H), 1.82–1.70 (m, 2H), 1.68–1.50 (m, 3H), 1.30–1.18
(m, 3H), 1.00 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.88 (s, 3H), 0.87 (s, 3H), 0.80 (s, 3H). 13C-NMR
(151 MHz, CDCl3) δ 174.01 (s), 172.09 (s), 171.88 (s), 148.43 (s), 144.00 (s), 125.43 (s), 120.50 (s), 115.13
(s), 114.27 (s), 81.19 (s), 59.37 (s), 49.04 (s), 48.09 (s), 47.24 (s), 44.99 (s), 41.12 (s), 39.95 (s), 36.70 (s), 29.30
(s), 28.17 (s), 27.33 (s), 24.85 (s), 24.71 (s), 23.51 (s), 21.48 (s), 19.83 (s), 18.93 (s), 13.74 (s).
1
(
7f). White solid. m/z = [M + 1] 515.3125, calculated value: 514.3042. H-NMR (600 MHz, CDCl3)
δ
7.40
(s, 1H), 6.98 (s, 1H), 6.64 (d, J = 12.2 Hz, 1H), 6.60–6.50 (m, 2H), 5.01–4.98 (m, 1H), 4.55 (dd, J = 8.4, 4.1
Hz, 1H), 3.71–3.65 (m, 1H), 3.53–3.37 (m, 1H), 3.35–3.22 (m, 1H), 2.36–2.29 (m, 1H), 2.27–2.17 (m, 1H),
2.06–1.97 (m, 2H), 1.91–1.83 (m, 1H), 1.81–1.70 (m, 2H), 1.69–1.53 (m, 3H), 1.33–1.21 (m, 3H), 1.02 (d, J =

Molecules 2017, 22, 1739
6 of 11
6.4 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.88 (s, 3H), 0.86 (s, 3H), 0.80 (s, 3H). 13C-NMR (151 MHz, CDCl3)
173.04 (s), 172.15 (s), 171.42 (s), 125.95 (s), 121.50 (s), 116.31 (s), 115.92 (s), 115.47 (s), 80.84 (s), 59.46 (s),
δ
56.42 (s), 49.02 (s), 48.09 (s), 47.63 (s), 44.83 (s), 42.51 (s), 36.52 (s), 29.93 (s), 29.12 (s), 27.26 (s), 24.97 (s),
24.78 (s), 22.60 (s), 21.87 (s), 19.20 (s), 18.98 (s), 13.72 (s).
(
7g). Light yellow solid. m/z = [M + 1] 541.3273, calculated value: 540.3199. 1H-NMR (600 MHz,
CDCl3) 8.18 (s, 1H), 7.47 (d, J = 15.6 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 6.94 (s, 1H), 6.87 (d, J = 8.2 Hz,
δ
1H), 6.27 (d, J = 15.6 Hz, 1H), 5.00–4.95 (m, 1H), 4.56 (dd, J = 8.5, 4.2 Hz, 1H), 3.89 (s, 3H), 3.70–3.64
(m, 1H), 3.54–3.39 (m, 1H), 3.36–3.20 (m, 1H), 2.38–2.29 (m, 1H), 2.26–2.19 (m, 1H), 2.07–1.99 (m, 2H),
1.93–1.84 (m, 1H), 1.83–1.71 (m, 2H), 1.71–1.54 (m, 3H), 1.34–1.20 (m, 3H), 1.03 (d, J = 6.5 Hz, 3H), 0.95
(d, J = 6.7 Hz, 3H), 0.89 (s, 3H), 0.87 (s, 3H), 0.81 (s, 3H). 13C-NMR (151 MHz, CDCl3)
δ 172.22 (s),
171.80 (s), 166.28 (s), 147.61 (s), 146.92 (s), 141.35 (s), 127.44 (s), 122.58 (s), 118.12 (s), 114.88 (s), 109.59
(s), 80.74 (s), 59.26 (s), 56.02 (s), 49.05 (s), 48.09 (s), 47.03 (s), 44.93 (s), 42.21 (s), 36.62 (s), 29.43 (s), 28.12
(s), 27.29 (s), 24.98 (s), 24.88 (s), 23.60 (s), 21.87 (s), 19.80 (s), 18.91 (s), 13.72 (s).
1
(
7h). White solid. m/z = [M + 1] 517.2924, calculated value: 516.2835. H-NMR (600 MHz, CDCl3)
δ
8.35 (s, 1H), 7.48 (s, 1H), 7.47 (s, 1H), 7.32 (s, 2H), 5.00–4.96 (m, 1H), 4.55 (dd, J = 8.3, 4.1 Hz, 1H),
3.71–3.66 (m, 1H), 3.55–3.41 (m, 1H), 3.36–3.27 (m, 1H), 2.35–2.25 (m, 1H), 2.23–2.18 (m, 1H), 2.05–1.98
(m, 2H), 1.97–1.86 (m, 1H), 1.84–1.75 (m, 2H), 1.72–1.53 (m, 3H), 1.35–1.22 (m, 3H), 1.02 (d, J = 6.6 Hz,
3H), 0.97 (d, J = 6.6 Hz, 3H), 0.91 (s, 3H), 0.87 (s, 3H), 0.81 (s, 3H).13C-NMR (151 MHz, CDCl3)
δ 174.21
(s), 171.81 (s), 166.27 (s), 148.45 (s), 148.47 (s), 144.00 (s), 121.60 (s), 120.58 (s), 114.31 (s), 80.68 (s), 59.25
(s), 56.12 (s), 49.02 (s), 48.05 (s), 47.00 (s), 44.91 (s), 42.31 (s), 36.66 (s), 29.42 (s), 28.11 (s), 27.30 (s), 24.98
(s), 24.89 (s), 23.60 (s), 21.85 (s), 19.82 (s), 18.89 (s), 13.71 (s).
3.2. ACE-Inhibitory Activity In Vitro
The preliminary biological investigations were conducted in vitro using the ACE-inhibition assay.
The experiments carried out for all the designed compounds (7a
–7h), for ACE-inhibitory activity at
five different concentrations (0.01–10 M), revealed that these newly synthesized compounds inhibited
µ
ACE in a dose-dependent manner (Figure 2). The evaluation results of all eight new compounds for
their ACE-inhibitory activity are presented in Table 1. Unfortunately, all of these new compounds
showed a comparatively lower ACE-inhibitory activity. Relatively, evaluation of IC50 data against
ACE for these compounds revealed that 7a and 7g are the best candidates and more encouraging
compounds with the lowest IC50 values of 6.76 and 6.88 µM, respectively. In contrast, the size of the
amino acid side chain had a great influence on the activity of these compounds. That is, the activity of
these compounds gradually declined when the size of the amino acid side chain increased. Besides,
the influence of phenolic acids on ACE-inhibitory activity was more obvious following the order:
protocatechuic acid > ferulic acid > gallic acid > 3,4-dihydroxybenzene acid. That is, substituents in
positions 3 and 4 in the benzene ring are beneficial to the increase of ACE-inhibitory activity. At the
same time, the shorter the amino side chain in phenolic acids, the better the ACE-inhibitory activity.
Table 1. ACE-inhibitory activity of each newly synthesized compound (IC50 values in µM).
Compound
Lisinopril
Compound Structure
IC50 (µM)
O
O
O
H
N
N
HO
<0.01
NH2

Molecules 2017, 22, 1739
7 of 11
Table 1. Cont.
Compound
7a
Compound Structure
IC50 (µM)
6.76 ± 0.96
7b
7c
13.94 ± 1.61
11.88 ± 1.82
13.46 ± 2.02
O
HO
N
O
7d
H
O
HO
HO
N
O
7e
10.58 ± 1.72
7f
7g
7h
13.97 ± 1.84
6.88 ± 0.85
13.25 ± 2.47
Note: The amount of hippuric acid (HA) released is directly proportional to the ACE activity. Briefly, ACE activity
was assayed by testing the release of HA from the hydrolysis of 0.3% (w/v) Hippuryl-L-Histidyl-L-Leucine Solution
(HHL) (Sigma-aldrich, St. Louis, MO, USA, No. H1635). The enzyme reaction (0.33 unit/mL, 50
adding 50 L of ACE enzyme, 200 L of 50 mM HEPES HCl buffer with 300 mM sodium chloride (pH 8.3) and
50
L HHL immediately mixed by swirling and incubated for 15 min at 37 ◦C. Then, 0.25 mL of 1 M HCl was
µL) was started by
µ
µ
µ
added followed by 2 mL ethyl acetate (Sigma, No. 27, 052-0). The solution was shaken vigorously for 60 s and then
centrifuged for 2 min. The clear upper layer (1.0 mL) was pipetted from each vial into corresponding 4-dram vials.
The ethyl acetate was evaporated in a boiling water bath and 3 mL deionized water was added. The solution was
mixed by inversion but not shaken. A spectrophotometer (U-3310) was used to record the absorbance of 228 nm.

Molecules 2017, 22, 1739
8 of 11
Figure 2. Dose-dependent angiotensin converting enzyme (ACE) inhibition activity of test compounds
and lisinopril (Lis). The results are presented as means ± SEM (n = 8).
3.3. ACE Molecular Docking
Based on the inhibition results, we selected the most potent compound 7a, our best ACE inhibitor
in this study, as a ligand example. To gain insight into the interaction of ACE with compound 7a, it
was docked on to tACE (PDB code: 1O86) using AutoDock Vina software [23]. As shown in Figure 3A,
7a and ligand compound (Lisinopril) of tACE can nearly overlap in the binding model. That is, they
have the same binding sites and have a similar combination model. The intermolecular interactions
between tACE binding site residues and predicted poses for compound 7a are presented in Figure 3B.
Results showed that the docking position of compound 7a showed a similar binding mode to that of
lisinopril. The intermolecular hydrogen-bonding interactions of 7a were mainly seen with the Gln281,
His 353, His 513, Tyr 522 and Tyr 523, which are partly similar to lisinopril.
Figure 3.
tACE; 1,
the tACE binding site.
(
A
) Docking confirmation of compound 7a (green) and ligand compound lisinopril (red) with
α
-helix; 2, random coil; 3, -sheet; ( ) Best expected binding mode of compound 7a (green) at
β
B

Molecules 2017, 22, 1739
9 of 11
3.4. Antihypertensive Tests In Vivo
In acute antihypertensive tests in vivo, the more potent and active compounds 7a and 7g were
investigated further using spontaneously hypertensive rats (SHRs). Lisinopril was used as a positive
control. The reduction in blood pressure (BP, systolic arterial pressure) of SHRs treated with compounds
7a and 7g at the same molar dose was slightly better than that of lisinopril under similar conditions.
Additionally, the antihypertensive activity of 7a and 7g occurred evidently 0.5 h after oral treatment and
lasted for four hours (Figure 4A,B). We then assessed the effects of compounds 7a and 7g in therapeutic
antihypertensive tests in SHRs. We found that BP in compound 7a- and 7g-treated (100 mg/kg, Po.
7days) rats was decreased remarkably on the second day after oral administration. Then, the BP
maintained at a relatively stable level. After drug withdrawal, the BP on the eighth day remained at a
lower level. However, the BP began to rebound starting from the ninth day, and it returned back to
the level before administration on the fourth day after drug withdrawal. Thus, compounds 7a and 7g
showed remarkable hypotensive activity in SHRs (Figure 4C), and the maximum antihypertensive
effect of the two compounds at a dose of 100 mg/kg daily was also approximately equivalent to that of
lisinopril (20 mg/kg/day). It is worth noting that successive dosing has no effect on the body weight
of the test rats in therapeutic antihypertensive tests.
200
A
7a 50 mg/Kg
7a 100 mg/Kg
180
Lisinopril
control
160
140
120
-120 -60
0
0
2
60 120 180 240 300 360
Time (Min.)
200
B
7g 50 mg/Kg
7g 100 mg/Kg
Lisinopril
180
160
140
120
control
-120 -60
60 120 180 240 300 360
Time (Min.)
7a 100 mg/Kg
7g 100 mg/Kg
200
C
180
160
140
120
Lisinopril
control
-2 -1
0
1
3 4 5 6 7 8 9 10 11 12 13 14
Days
Figure 4.
hypertension rats (SHRs) for single dose administration (dosing time: 0 min); (
antihypertensive activity of compounds 7a and 7g in SHRs for 7 days treatment (dosing time: 0 day;
blood pressure (BP) measured time: 9:30–11:30 am). Data are presented as mean SEM, n = 6. The BP
(A
,
B), the acute antihypertensive activity of compounds 7a and 7g in spontaneously
C) the therapeutic
±
was determined with a BP-2010A Storage Pressure Meter. This system measures BP by recording
the cuff pressure at which the interrupted blood flow returns to the tail. Before drug administration,
training consisted of five sessions over 3 days. The SHRs were placed into a thermostatically controlled
Lucite box of the Visitech system BP2010A, and heated on a heated pad maintained at 37 ◦C for
2 min before BP measurement started. The tail root of SHR was surrounded by an inflatable tubular
sleeve, and a pulse electron detector was placed in the root of the tails. Then BP was measured after
the computer provided a stable signal. The BP for the session was accepted as the average of five
BP readings that were within 10 mm Hg. The average BP values were calculated by employing the
ANOVA method.

Molecules 2017, 22, 1739
10 of 11
4. Conclusions
In conclusion, we developed an efficient and shortcut method for drug discovery based on
both the means of combinatorial chemistry and pharmaceutical design philosophy of traditional
Chinese medicine. We call this method combination of traditional Chinese medicine chemistry
(CTCMC). Using this method, and inspired by the “Danshen-borneol” drug pair and some classical
ACE inhibitors, we designed eight novel peptidomimetics (phenolic acid-Pro-borneol) compounds,
which were successively synthesized and evaluated in vitro and in vivo as potential ACE inhibitors
with less side effects. Of these, bornyl esters of 7a and 7g exhibited good in vivo ACE-inhibitory
activity. These two compounds are most likely acting as prodrugs since both were found to have
moderate activity in vitro as inhibitors of ACE. Based on these preliminary and promising results,
more suitable modifications in the phenolic moieties and amino acid residue adjoining proline are
under development. This class of novel molecules, combined with their detailed antihypertensive
activities, will be useful for future drug development and shall be presented in the near future.
Acknowledgments: This work was supported by the Development and Application of Supercritical Fluid
Chromatography (2013YQ170525; subproject: Application Research of Supercritical Fluid Chromatography in
Chinese Traditional Medicine and Its Metabolites, 2013YQ17052509), Program for Changjiang Scholars and
Innovative Research Team in University of Ministry of Education of China (IRT_15R55), the project for Innovative
Research Team of Research and Technology of Shaanxi Province (2013KCT-24), the Technology Support Plan
Project (2008BAI51B01), National Natural Science Foundation of China (20875074), and the Seventh Group of
Hundred-Talent Program of Shaanxi Province (2015), and Natural Science Foundation of Shaanxi Province, China
(Grant No. 2017JM8054).
Author Contributions: Yajun Bai and Xiaohui Zheng designed the research; Ying Sun, Pei Liu, and Xufei Chen
performed experiments; Yujun Bai and Zefeng Zhao analyzed the data; Xirui He and Yajun Bai wrote or contributed
to the writing of the manuscript.
Conflicts of Interest: The authors declare that there is no conflict of interest.
References
1.
Os, I.; Hjermann, I.; Nordby, G. Hypertension as a part of metabolic cardiovascular syndrome.
Tidsskr. Nor. Laegeforen. 1991, 111, 3062–3064. [PubMed]
2.
Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension:
Analysis of worldwide data. Lancet 2005, 365, 217–223. [CrossRef]
3.
4.
5.
Wong, T.Y.; Wong, T.; Mitchell, P. The eye in hypertension. Lancet 2007, 369, 425–435. [CrossRef]
Messerli, F.H.; Williams, B.; Ritz, E. Essential hypertension. Lancet 2007, 370, 591–603. [CrossRef]
Anonymous. Angiotensin II receptor antagonists and heart failure: Angiotensin-converting-enzyme
inhibitors remain the first-line option. Prescrire Int. 2005, 14, 180–186.
6.
7.
8.
Thurston, H. Angiotensin-converting enzyme inhibition as first-line treatment for hypertension. Clin. Exp.
Pharmacol. Physiol. Suppl. 1992, 19, 67–71. [CrossRef] [PubMed]
Antonios, T.F.T.; MacGregor, G.A. Angiotensin converting enzyme inhibitors in hypertension: Potential
problems. J. Hypertens. 1995, 13, S11–S16. [CrossRef]
Israili, Z.H.; Hall, W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme
inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 1992, 117, 234–242.
[CrossRef] [PubMed]
9.
Galardy, R.E. Inhibition of angiotensin-converting enzyme by phosphoramidates and polyphosphates.
Biochemistry 1982, 21, 5777–5781. [CrossRef] [PubMed]
10. Thorsett, E.D.; Harris, E.E.; Peterson, E.R.; Greenlee, W.J.; Patchett, A.A.; Ulm, E.H.; Vassil, T.C.
Phosphorus-containing inhibitors of angiotensin-converting enzyme. Proc. Natl. Acad. Sci. USA 1982
79, 2176–2180. [CrossRef] [PubMed]
,
11. Galardy, R.E. Inhibition of angiotensin-converting enzyme with Nα-phosphoryl-L-alanyl-L-proline and
Nα-phosphoryl-L-valyl-L-tryptophan. Biochem. Biophys. Res. Commun. 1980, 97, 94–99. [CrossRef]
12. Galardy, R.E.; Kontoyiannidou-Ostrem, V.; Kortylewicz, Z.P. Inhibition of angiotensin converting enzyme by
phosphonic amides and phosphonic acids. Biochemistry 1983, 22, 1990–1995. [CrossRef] [PubMed]

Molecules 2017, 22, 1739
11 of 11
13. Wu, Y.-B.; Ni, Z.-Y.; Shi, Q.-W.; Dong, M.; Kiyota, H.; Gu, Y.-C.; Cong, B. Constituents from Salvia Species
and Their Biological Activities. Chem. Rev. 2012, 112, 5967–6026. [CrossRef] [PubMed]
14. Song, J.; Bi, H.; Xie, X.; Guo, J.; Wang, X.; Liu, D. Natural borneol enhances geniposide ophthalmic absorption
in rabbits. Int. J. Pharm. 2013, 445, 163–170. [CrossRef] [PubMed]
15. Liu, J.; Fu, S.; Wei, N.; Hou, Y.; Zhang, X.; Cui, H. The effects of combined menthol and borneol on fluconazole
permeation through the cornea ex vivo. Eur. J. Pharmacol. 2012, 688, 1–5. [CrossRef] [PubMed]
16. Bala, M.; Qadar Pasha, M.A.; Bhardwaj, D.K.; Pasha, S. Novel peptidomimics as angiotensin-converting
enzyme inhibitors: A combinatorial approach. Bioorg. Med. Chem. 2002, 10, 3685–3691. [CrossRef]
17. Chen, C.H.; Lin, J.Y.; Lin, C.N.; Hsu, S.Y. Inhibition of Angiotensin-I-Converting Enzyme by
Tetrahydroxyxanthones Isolated from Tripterospermum lanceolatum. J. Nat. Prod. 1992, 55, 691–695.
[CrossRef] [PubMed]
18. Alam, M.A.; Sernia, C.; Brown, L. Ferulic Acid Improves Cardiovascular and Kidney Structure and Function
in Hypertensive Rats. J. Cardiovasc. Pharmacol. 2013, 61, 240–249. [CrossRef] [PubMed]
19. Actis-Goretta, L.; Ottaviani, J.I.; Fraga, C.G. Inhibition of Angiotensin Converting Enzyme Activity by
Flavanol-Rich Foods. J. Agric. Food Chem. 2005, 54, 229–234. [CrossRef] [PubMed]
20. Siltari, A.; Viitanen, R.; Kukkurainen, S.; Vapaatalo, H.; Valjakka, J. Does the cis/trans configuration of
peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition? Biol. Targets Ther. 2014, 8,
59–65.
21. Vermeirssen, V.; van Camp, J.; Verstraete, W. Bioavailability of angiotensin I converting enzyme inhibitory
peptides. Br. J. Nutr. 2004, 92, 357–366. [CrossRef] [PubMed]
22. Byun, H.-G.; Kim, S.-K. Structure and activity of angiotensin I converting enzyme inhibitory peptides derived
from Alaskan pollack skin. J. Biochem. Mol. Biol. 2002, 35, 239–243. [CrossRef] [PubMed]
23. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring
function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [CrossRef]
[PubMed]
Sample Availability: Samples of the compounds 7a–7h are available from the author Yajun Bai.
©
2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).